Evidence map›Paper›PMID 35431306›Full record

ReviewInternal medicine (Tokyo, Japan)2022

Effects of Atezolizumab and Bevacizumab on Adrenal Gland Metastasis of Hepatocellular Carcinoma: A Case Report and Review of Literature.

Natsuki Ishikawa, Kenya Kamimura, Saori Endo, Soichi Ishii, Kazuya Ogawa, Norihiro Sakai, Hiroyuki Abe, Masayoshi Ko, Osamu Shibata, Youhei Koseki and 3 more

Open access · diamondAbstract readReviewCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Review in Internal medicine (Tokyo, Japan), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact, top 95% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 0 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 1 institution in 1 country.

Natsuki IshikawaDivision of Gastroenterology and Hepatology, Graduate School of Medical and Dental Sciences, Niigata University, Japan.
Kenya KamimuraDivision of Gastroenterology and Hepatology, Graduate School of Medical and Dental Sciences, Niigata University, Japan.
Saori EndoDivision of Gastroenterology and Hepatology, Graduate School of Medical and Dental Sciences, Niigata University, Japan.
Soichi IshiiDivision of Gastroenterology and Hepatology, Graduate School of Medical and Dental Sciences, Niigata University, Japan.
Kazuya OgawaDivision of Gastroenterology and Hepatology, Graduate School of Medical and Dental Sciences, Niigata University, Japan.
Norihiro SakaiDivision of Gastroenterology and Hepatology, Graduate School of Medical and Dental Sciences, Niigata University, Japan.
Hiroyuki AbeDivision of Gastroenterology and Hepatology, Graduate School of Medical and Dental Sciences, Niigata University, Japan.
Masayoshi KoDivision of Gastroenterology and Hepatology, Graduate School of Medical and Dental Sciences, Niigata University, Japan.
Osamu ShibataDivision of Gastroenterology and Hepatology, Graduate School of Medical and Dental Sciences, Niigata University, Japan.
Youhei KosekiDivision of Gastroenterology and Hepatology, Graduate School of Medical and Dental Sciences, Niigata University, Japan.
Junji YokoyamaDivision of Gastroenterology and Hepatology, Graduate School of Medical and Dental Sciences, Niigata University, Japan.
Akira SakamakiDivision of Gastroenterology and Hepatology, Graduate School of Medical and Dental Sciences, Niigata University, Japan.
Shuji TeraiDivision of Gastroenterology and Hepatology, Graduate School of Medical and Dental Sciences, Niigata University, Japan.
Niigata University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Regarding the prognosis of cases with advanced-stage hepatocellular carcinoma (HCC), a recent clinical study showed that the immune checkpoint inhibitors atezolizumab plus bevacizumab have superior efficacy to sorafenib. However, only a few reports have focused on their effects on extrahepatic metastases. We herein report a case of HCC in a 59-year-old man with intrahepatic lesions treated successfully by hepatic arterial chemoembolization, radiotherapy, and sorafenib; the extrahepatic lesion in the adrenal gland was treated by atezolizumab plus bevacizumab. The patient showed a tumor-free condition for one year. We have summarized the clinical course and reviewed the literature to underscore the efficacy of atezolizumab plus bevacizumab for treating extrahepatic lesions of HCC.

Indexed as

Adrenal Gland NeoplasmsCarcinoma, HepatocellularLiver NeoplasmsAdrenal GlandsAntibodies, Monoclonal, HumanizedBevacizumabHumansMaleMiddle AgedSorafenibAntibodies, Monoclonal, HumanizedatezolizumabBevacizumabSorafenibadrenal glandatezolizumab plus bevacizumabhepatocellular carcinomametastasis

Identifiers

PMID35431306
PMCPMC9683801
OpenAlexW4224288804

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.